Patents by Inventor Roderick Wayland Bates

Roderick Wayland Bates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS FOR TREATING TUBERCULOSIS
    Publication number: 20230348436
    Abstract: The invention concerns a compound of formula (Ia) or (lb) wherein R1 is hydrogen or a methyl group; R2 is an unsubstituted or substituted alkyl group; R3 is an aryl group or a heteroaryl group, optionally substituted by one or more groups selected from halogen, alkyl or alkoxy; and, in Formula (Ia), X is CH or N and Y is NH, S or O, or, in Formula (Ib), X is NH, S or O and Y is CH or N. The invention further concerns a method of synthesizing the inventive compound, a composition comprising the inventive compound or a pharmaceutically acceptable salt thereof and bedaquiline (BDQ), an analogue of bedaquiline (BDQ) or a mixture thereof, and the use of said composition or compound for the treatment of tuberculosis.
    Type: Application
    Filed: November 26, 2020
    Publication date: November 2, 2023
    Applicants: NANYANG TECHNOLOGICAL UNIVERSITY, AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH
    Inventors: Gerhard GRUBER, Roderick Wayland BATES, Shuyi Pearly NG
  • Compounds for treating tuberculosis
    Patent number: 11078165
    Abstract: The present invention relates to pyrimidine compounds and compositions for treating tuberculosis. These compounds may be used to target the F1 domain of F-ATP synthase and may be used with bedaquiline or 6-chloro-2-ethyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl]phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide (Q203) or a combination thereof.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: August 3, 2021
    Assignees: NANYANG TECHNOLOGICAL UNIVERSITY, NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Gerhard Grüber, Roderick Wayland Bates, Adam Hotra, Thomas Dick, Kevin Pethe
  • COMPOUNDS FOR TREATING TUBERCULOSIS
    Publication number: 20200231550
    Abstract: The present invention relates to pyrimidine compounds and compositions for treating tuberculosis. These compounds may be used to target the F1 domain of F-ATP synthase and may be used with bedaquiline or 6-chloro-2-ethyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl]phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide (Q203) or a combination thereof.
    Type: Application
    Filed: February 15, 2018
    Publication date: July 23, 2020
    Applicants: NANYANG TECHNOLOGICAL UNIVERSITY, NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Gerhard GRÜBER, Roderick Wayland BATES, Adam HOTRA, Thomas DICK, Kevin PETHE
  • Intravascular contrast agents
    Patent number: 8911710
    Abstract: Intravascular contrast agents are provided by Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C2-4alkylene and C3-5alkynylene. The chelates may be used as an intravascular contrast agent for MRI. Certain embodiments demonstrate enhanced relaxivity and good levels of signal enhancement.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: December 16, 2014
    Assignees: Agency for Science, Technology and Research, Nanyang Technological University
    Inventors: Roderick Wayland Bates, Xavier Golay, Changtong Yang
  • Surface Acoustic Wave Resonator
    Publication number: 20120223616
    Abstract: According to embodiments of the present invention, a surface acoustic wave resonator is provided.
    Type: Application
    Filed: October 29, 2010
    Publication date: September 6, 2012
    Inventors: Roderick Wayland Bates, Xavier Golay, Changtong Yang
  • INTRAVASCULAR CONTRAST AGENTS
    Publication number: 20110268663
    Abstract: Intravascular contrast agents are provided by Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C2-4alkylene and C3-5alkynylene. The chelates may be used as an intravascular contrast agent for MRI. Certain embodiments demonstrate enhanced relaxivity and good levels of signal enhancement.
    Type: Application
    Filed: May 9, 2011
    Publication date: November 3, 2011
    Inventors: Roderick Wayland Bates, Xavier Golay, Changtong Yang